Pharmacokinetic Considerations of New Insulin Formulations and Routes of Administration

SummaryThere is a continuing search for improved insulin formulations in order to imitate as closely as possible the physiological pattern of insulin secretion, and thereby to minimise the complications of diabetes mellitus. The major advances achieved to date are in the area of human insulin analogue synthesis resulting from the introduction of recombinant DNA techniques, and in improved delivery systems that utilise noninvasive or minimally invasive modes of administration.To accommodate postprandial hyperglycaemia, monomeric insulin formulations have been developed, of which insulin lispro (the Lys-Pro analogue) is already approved for clinical use. These formulations have a rapid rate of absorption and, therefore, have to be administered at meal time (unlike the previous short-acting formulations). Their residence time is also about 2-fold shorter than regular human insulin; this minimises the risk of the excessive hypoglycaemic effect that characterises regular human insulin formulations. Certain proinsulin formulations with hepatoselective activity have been developed but were found to be poorly tolerated. The newer proinsulin molecules do not show hepatoselective properties.In order to generate basal insulin levels, peakless long-acting formulations have been developed, including: a soluble formulation (which upon subcutaneous administration, produces a ‘depot-like’ sustained release mechanism), albumin-bound insulin and cobalt-insulin hexamer formulations. To improve patient compliance the ‘pen’ device was developed for subcutaneous injections. Programmable infusion pumps were developed to avoid repetitive subcutaneous injections.Great efforts have been made in searching for noninvasive modes of insulin administration that will avoid the need for parenteral administration. These include: oral, colonic, rectal, nasal, ocular, buccal, pulmonary, uterine and transdermal routes of administration. Various enhancers have been tested to increase the bioavailability of each route. At present these alternative routes do not provide clinically relevant substitutes for the subcutaneous mode of administration.In conclusion, although the newer formulations provide certain advantages, there is still much to be done to further facilitate and improve insulin therapy.

[1]  C. Saudek Future Developments in Insulin Delivery Systems , 1993, Diabetes Care.

[2]  R. Eaton,et al.  The Intravenous, Intraperitoneal, and Subcutaneous Routes of Insulin Delivery in Diabetic Man , 1979, Diabetes.

[3]  C. Gargiulo,et al.  Insulin delivery in nosedrops: new formulations containing alkylglycosides. , 1994, Endocrinology.

[4]  G. Ward,et al.  Effects of Prolonged Pulsatile Hyperinsulinemia in Humans: Enhancement of Insulin Sensitivity , 1990, Diabetes.

[5]  W. Ritschel,et al.  Rectal administration of insulin. , 1984, Methods and findings in experimental and clinical pharmacology.

[6]  S. Davis,et al.  Intranasal Insulin , 1992, Clinical pharmacokinetics.

[7]  U. Ribel,et al.  Action Profile of Cobalt(III)-Insulin: A Novel Principle of Protraction of Potential Use for Basal Insulin Delivery , 1995, Diabetes.

[8]  J. Galloway Treatment of NIDDM With Insulin Agonists or Substitutes , 1990, Diabetes Care.

[9]  J. Gerich,et al.  Adverse Effects of Insulin Antibodies on Postprandial Plasma Glucose and Insulin Profiles in Diabetic Patients Without Immune Insulin Resistance: Implications for Intensive Insulin Regimens , 1987, Diabetes.

[10]  J. Palmer,et al.  Insulin antibodies in insulin-dependent diabetics before insulin treatment. , 1983, Science.

[11]  C. Binder Absorption of injected insulin. A clinical-pharmacological study. , 2009, Acta pharmacologica et toxicologica.

[12]  P. Hildebrandt,et al.  Basal Rate Subcutaneous Insulin Infusion: Absorption Kinetics and Relation to Local Blood Flow , 1988, Diabetic medicine : a journal of the British Diabetic Association.

[13]  D R Owens,et al.  Monomeric Insulins and Their Experimental and Clinical Implications , 1990, Diabetes Care.

[14]  Y. Yamasaki,et al.  Effect of addition of hyaluronic acid to highly concentrated insulin on absorption from the conjunctiva in conscious diabetic dogs , 1994, The Journal of pharmacy and pharmacology.

[15]  R. Kawamori,et al.  Effectiveness of insulin suppositories in diabetic patients , 1989, The Journal of pharmacy and pharmacology.

[16]  G. Schernthaner,et al.  Immunogenicity and Allergenic Potential of Animal and Human Insulins , 1993, Diabetes Care.

[17]  G. Chiou,et al.  Improvement of systemic absorption of insulin through eyes with absorption enhancers. , 1989, Journal of pharmaceutical sciences.

[18]  R. Bergman,et al.  Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. , 1990, The American journal of physiology.

[19]  D Rodbard,et al.  Computer Simulation of Plasma Insulin and Glucose Dynamics After Subcutaneous Insulin Injection , 1989, Diabetes Care.

[20]  G. Dimitriadis,et al.  Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus. , 1986, Metabolism: clinical and experimental.

[21]  B. Linde Dissociation of Insulin Absorption and Blood Flow During Massage of a Subcutaneous Injection Site , 1986, Diabetes Care.

[22]  W. Ritschel,et al.  Development of a colonic release capsule dosage form and the absorption of insulin. , 1992, Methods and findings in experimental and clinical pharmacology.

[23]  D. Salomon,et al.  Heterogeneity and contact-dependent regulation of hormone secretion by individual B cells. , 1986, Experimental cell research.

[24]  R. Turner,et al.  Pulsatile Insulin Has Greater Hypoglycemic Effect Than Continuous Delivery , 1983, Diabetes.

[25]  J. Radziuk,et al.  An adaptive plasma glucose controller based on a nonlinear insulin/glucose model , 1994, IEEE Transactions on Biomedical Engineering.

[26]  E. Kraegen,et al.  Pharmacokinetics of Insulin Implications for Continuous Subcutaneous Insulin Infusion Therapy , 1985, Clinical pharmacokinetics.

[27]  H. Sasaki,et al.  Effect of Preservatives on Systemic Delivery of Insulin by Ocular Instillation in Rabbits , 1994, The Journal of pharmacy and pharmacology.

[28]  A. Turner-Henson,et al.  Insulin administration to the eyes of normoglycemic human volunteers. , 1994, Journal of ocular pharmacology.

[29]  B. Tirosh,et al.  The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools , 1997 .

[30]  I. Wilding,et al.  The Distribution of an Intranasal Insulin Formulation in Healthy Volunteers: Effect of Different Administration Techniques , 1994, The Journal of pharmacy and pharmacology.

[31]  F. Matschinsky,et al.  New perspectives on pancreatic islet glucokinase. , 1984, The American journal of physiology.

[32]  P. Brunetti,et al.  Effects of the Short-Acting Insulin Analog [Lys(B28),Pro(B29)] on Postprandial Blood Glucose Control in IDDM , 1996, Diabetes Care.

[33]  P. Home,et al.  Insulin treatment: a decade of change. , 1989, British medical bulletin.

[34]  J. Santiago Insulin Therapy in the Last Decade: A pediatric perspective , 1993, Diabetes Care.

[35]  K. Tachibana,et al.  Transdermal delivery of insulin by ultrasonic vibration , 1991, The Journal of pharmacy and pharmacology.

[36]  D. Howey,et al.  Establishment of Time-Action Profiles for Regular and NPH Insulin Using Pharmacodynamic Modeling , 1994, Diabetes Care.

[37]  E. Berry,et al.  Bile salts promote the absorption of insulin from the rat colon. , 1981, Life sciences.

[38]  J. K. Radder,et al.  In Vivo Relationship Between Insulin Clearance and Action in Healthy Subjects and IDDM Patients , 1990, Diabetes.

[39]  T L Blundell,et al.  The structure of 2Zn pig insulin crystals at 1.5 A resolution. , 1988, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[40]  E. Ziv,et al.  Rectal administration of insulin. , 1984, Israel journal of medical sciences.

[41]  D R Matthews,et al.  Physiological Implications of Pulsatile Hormone Secretion , 1991, Annals of the New York Academy of Sciences.

[42]  E. Ziv,et al.  Oral administration of insulin in solid form to nondiabetic and diabetic dogs. , 1994, Journal of pharmaceutical sciences.

[43]  A. Vaag,et al.  NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue. , 1989, BMJ.

[44]  T. W. Haeften Clinical significance of insulin antibodies in insulin-treated diabetic patients. , 1989 .

[45]  R. Greenwood,et al.  Buccal administration of human insulin in streptozocin-diabetic rats. , 1993, Research communications in chemical pathology and pharmacology.

[46]  A. Yamamoto,et al.  Absorption Enhancement of Intrapulmonary Administered Insulin by Various Absorption Enhancers and Protease Inhibitors in Rats , 1994, The Journal of pharmacy and pharmacology.

[47]  G. Paolisso,et al.  Pulsatile insulin delivery is more efficient than continuous infusion in modulating islet cell function in normal subjects and patients with type 1 diabetes. , 1988, The Journal of clinical endocrinology and metabolism.

[48]  B H Frank,et al.  Altering the association properties of insulin by amino acid replacement. , 1992, Protein engineering.

[49]  S. Mitragotri,et al.  Ultrasound-mediated transdermal protein delivery , 1995, Science.

[50]  G. Golomb,et al.  Pharmacokinetics and pharmacodynamics of trans-endometrial administered peptides and macromolecules , 1995 .

[51]  G. K. Adams,et al.  Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. , 1993, JAMA.

[52]  G. Williams,et al.  Changes in Blood Flow Close to Subcutaneous Insulin Injection Sites in Stable and Brittle Diabetics , 1983, Diabetes.

[53]  D R Owens,et al.  Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties: Evidence From Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans , 1991, Diabetes Care.

[54]  B. Clarke,et al.  The Importance of the Time Interval Between Insulin Injection and Breakfast in Determining Postprandial Glycaemic Control—A Comparison Between Human and Porcine Insulin , 1988, Diabetic medicine : a journal of the British Diabetic Association.

[55]  Chance Re,et al.  Improving Insulin Therapy: Achievements and Challenges , 1994 .

[56]  L. Heinemann,et al.  Clinical Pharmacology of Human Insulin , 1993, Diabetes Care.

[57]  J. Brange,et al.  Neutral Insulin Solutions Physically Stabilized by Addition of Zn2+ , 1986, Diabetic medicine : a journal of the British Diabetic Association.

[58]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[59]  D. Brems,et al.  Improved insulin stability through amino acid substitution. , 1992, Protein engineering.

[60]  B. Zinman The Physiologic Replacement of Insulin , 1989 .

[61]  W. Malaisse Metabolic signaling of insulin secretion , 1996 .

[62]  W. Waldhäusl,et al.  Efficacy of Pulsatile Versus Continuous Insulin Administration on Hepatic Glucose Production and Glucose Utilization in Type I Diabetic Humans , 1986, Diabetes.

[63]  K. Polonsky,et al.  Hypoglycemic potency and metabolic clearance rate of intravenously administered human proinsulin and metabolites. , 1990, Endocrinology.

[64]  J. Brange Galenics of Insulin , 1987 .

[65]  D. Howey,et al.  [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.

[66]  D. Owens,et al.  Relationship Between Absorption of Radiolabeled Soluble Insulin, Subcutaneous Blood Flow, and Anthropometry , 1992, Diabetes Care.

[67]  D. Howey,et al.  Biosynthetic Human Proinsulin: Review of Chemistry, in Vitro and in Vivo Receptor Binding, Animal and Human Pharmacology Studies, and Clinical Trial Experience , 1992, Diabetes Care.

[68]  J. Woodley Enzymatic barriers for GI peptide and protein delivery. , 1994, Critical reviews in therapeutic drug carrier systems.

[69]  D. Brems,et al.  Synthesis of a Fast-Acting Insulin Based on Structural Homology with Insulin-Like Growth Factor I, , 1992 .

[70]  B H Frank,et al.  Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. , 1988, The American journal of physiology.

[71]  E. Ferrannini,et al.  Kinetic analysis of plasma insulin disappearance in nonketotic diabetic patients and in normal subjects. A tracer study with 125I-insulin. , 1978, The Journal of clinical investigation.

[72]  P. Brunetti,et al.  Improved Postprandial Metabolic Control After Subcutaneous Injection of a Short-Acting Insulin Analog in IDDM of Short Duration With Residual Pancreatic β-Cell Function , 1995, Diabetes Care.

[73]  A. Caumo,et al.  Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects. , 1993, The Journal of clinical endocrinology and metabolism.

[74]  R. DeFronzo The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.

[75]  E. Joslin,et al.  Joslin's Diabetes Mellitus , 1971 .

[76]  M. Vranic,et al.  Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs. , 1992, The Journal of clinical investigation.

[77]  J. C. Scott-Moncrieff,et al.  Enhancement of intestinal insulin absorption by bile salt-fatty acid mixed micelles in dogs. , 1994, Journal of pharmaceutical sciences.